报价延迟最少15分钟:2025/09/15 15:48 EDT
盘后时段
|
||||
|
-- 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.585
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.93/2.42
|
|
企业价值
25.83B
|
| 资产负债 |
|
每股账面净值
13.36
|
| 现金流量 |
|
现金流量率
0.17
|
| 损益表 |
|
收益
80.80M
|
|
每股收益
13.27
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/15 15:48 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations. |
